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Background/Aims
Rikkunshito (TJ-43), an herbal medicine, has been demonstrated to relieve gastroesophageal reflux symptoms. However, the ef-
fects of TJ-43 on esophageal motor functions have not been fully determined. This double-blind crossover study was per-
formed to investigate the effects of TJ-43 on esophageal motor functions and gastroesophageal reflux.
Methods
The subjects were 10 normal male volunteers. Lower esophageal sphincter pressure and esophageal body peristaltic con-
tractions with and without 1-week administration of TJ-43 were examined in a crossover fashion. Post-prandial gastro-
esophageal reflux was also determined using a multi-channel impedance pH dual monitor.
Results
TJ-43 at a standard dose of 7.5 g/day did not significantly augment esophageal peristaltic contraction pressure measured in 
the proximal, middle and distal segments of the esophagus, whereas increment of resting lower esophageal sphincter pressure 
was observed in a supine position. In addition, TJ-43 administration did not decrease post-prandial gastroesophageal acid, 
non-acid reflux events or accelerate esophageal clearance time.
Conclusions
TJ-43 at a standard dose did not have a significant effect on esophageal motor activity or gastroesophageal reflux in healthy 
adults. 
(J Neurogastroenterol Motil 2012;18:181-186)
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Introduction
Gastroesophageal reflux disease (GERD) is a disease fre-
quently encountered in gastroenterology clinics in both western 
countries and Japan.
1-4 Decreased esophageal motor function is 
one of the most important factors for occurrence of GERD,
5 
thus, prokinetic agents that increase lower esophageal sphincter Terumi Morita, et al
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(LES) pressure and esophageal body contraction are considered 
to be effective for treatment of GERD patients. The powder ex-
tract of the herbal medicine, rikkunshito, has been reported to be 
effective in improving various upper gastro-intestinal symptoms, 
and is widely administrated to patients with GERD and func-
tional dyspepsia (FD) in Japan.
6-10 Rikkunshito, extracted from a 
mixture of Atractylodis Lanceae Rhizoma, Ginseng Radix, 
Pinelliae Tuber, Hoelen, Zizyphi Fructus, Aurantii Nobilis 
Percarpium, Glycyrrhizae Radix and Zingiberis Rhizoma, is 
manufactured and distributed as TJ-43 by Tsumura Co. (Tokyo, 
Japan).
11 Several studies have demonstrated that TJ-43 stim-
ulates gastric motor activities and accelerate gastric empty-
ing.
7,10,12 However, the effects of TJ-43 on esophageal motor 
functions have not been fully examined, though it was reported to 
be effective for relief of reflux symptoms, such as heartburn and 
acid regurgitation.
6,7,9,13 We conducted the present double-blind 
crossover study to clarify the effects of TJ-43 on esophageal mo-
tor functions and gastroesophageal reflux events. 
Materials and Methods
We studied 10 healthy male volunteers (22.8 ± 2.0 years 
old) who had no history of gastrointestinal surgery and received 
no medication which might have affected gastroesophageal 
function. 
Esophageal motor function and post-prandial gastroeso-
phageal reflux were determined after a 7-day administration of 
TJ-43 or a placebo in random order using a double-blind cross-
over design. TJ-43 at 2.5 g was administrated 3 times per day 
(commonly used for adult patients in Japan with GERD and FD 
symptoms) 30 minutes before each meal. Lactose was used as the 
placebo drug. TJ-43 or the placebo was placed in identical capsu-
les by 2 pharmacists (Tomochika Uemura and Kohji Naora) to 
conceal the contents, and the contents of the capsules were un-
known to the examiners of esophageal motor function and 
post-prandial gastroesophageal reflux. 
All subjects were tested after 7-day administrations of TJ-43 
and the placebo, with at least 1-week interval between. On the last 
day of administration, determinations of esophageal motor func-
tion and post-prandial gastroesophageal reflux were performed. 
We examined esophageal motor function using high-resolution 
36-channel manometry (ManoScan
360TM; Sierra Scientific 
Instruments, Los Angeles, CA, USA).
14-16 Briefly, prior to each 
measurement, the transducers were calibrated according to the 
manufacturer’s instructions, then a manometric catheter was in-
serted transnasally using a small amount of 2% lidocaine jelly 
(Xylocaine jelly; AstraZeneka Co., Osaka, Japan). The measure-
ments were started 5 minutes after insertion for stabilization with 
the subject in a sitting position. Initially, we determined resting 
LES pressure for at least 5 minutes, then measured esophageal 
body peristaltic contractions after the subject drank 5 mL of 
water. That, was repeated at intervals of 2 minutes until we ob-
tained 5 complete contraction records. After finishing the deter-
mination of esophageal motor activity in a sitting position, the in-
traesophageal pressure measurements were repeated in the same 
manner with the subject in a supine position. For analysis, the 
esophageal body peristaltic contractions were divided into 3 seg-
ments from segments 1 to 3 (proximal, middle and distal) by 2 
contraction troughs, as reported previously.
17-20 The maximum 
peristaltic contractions in each segment were determined, then 
the mean of 5 individual contractions was calculated as used as 
the contraction value for each of the segments in each subject.
Following the esophageal motor function tests, we utilized a 
composite 6-channel impedance and 2-channel pH sensor cathe-
ter (Sandhill Scientific Inc., Highlands Ranch, CO, USA) that 
was inserted transnasally after calibration with a buffer solution at 
pH 4.0 and 7.0, according to the manufacturer’s instructions. 
We placed the impedance sensors at 3, 5, 7, 9, 15 and 17 cm 
above the LES, and the esophageal pH at 5 cm above the LES. 
One hour after insertion of the catheter for impedance and pH 
determination, a standardized 1,617 kcal high caloric meal was 
supplied and consumed within 20 minutes. This high caloric 
meal consisted of a large plate of rice and curry, as well as cheese 
and tuna soup (S&B Foods Inc., Tokyo; Hagoromo Foods 
Company, Shizuoka; and Ajinomoto Company, Tokyo, Japan), 
and contained 49.7 g of protein, 220.3 g of carbohydrates and 
59.8 g of fat. Data collection using a multichannel intraluminal 
impedance-pH monitoring system (Sleuth
TM; Sandhill Scientific 
Inc.) was performed during the 3-hour period after the meal. We 
then utilized a computerized algorithm (Autoscan; Sandhill 
Scientific Inc.) to identify reflux episodes as changes in im-
pedance from the distal to proximal esophagus over time. The 
tracings thus obtained were manually reviewed to confirm that 
the reflux episodes were correctly identified by the automated 
algorithm. Reflux episodes were classified as follows: (1) liquid 
only (decrease in impedance progressing proximally), (2) gas on-
ly (rise in impedance above 3,000 Ω in at least 2 channels pro-
gressing proximally) and (3) mixed (gas-liquid: a combination of 
liquid and gas impedance patterns).
21-23 We then further ana-
lyzed the liquid only and mixed reflux episodes to determine the Rikkunshito and Esophageal Functions
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Figure 1. Resting lower esophageal sphincter (LES) pressure in sitting and supine positions determined during TJ-43 and placebo administrations. 
LES pressure was higher during TJ-43 administration in the supine position, though the difference was not significant.
acidity of the refluxes. Finally, reflux episodes were classified as: 
(1) acidic, for those with a nadir pH recorded during a mu-
tichannel intraluminal impedance-detected reflux pattern that 
was less than 4.0; (2) weakly acidic, when pH declined more than 
1.0 and the nadir was between 4.0 and 7.0; and (3) non-acidic, in 
instances when the pH nadir was greater than 7.0.
23
A Wilcoxon signed rank test was used to compare paired 
data. All calculations were done with Stat View 5.0 software 
(Abacus Concepts Inc., Berkeley, CA, USA) for Macintosh. 
Data were expressed as the mean ± SE. A difference level of P < 
0.05 was considered to be significant.
This study was performed according to the declaration of 
Helsinki and the study protocol was approved by the ethical com-
mittee of Shimane University Faculty of Medicine. Written in-
formed consent was obtained from each of the study subjects be-
fore enrollment. 
Results
Resting LES pressures in the sitting and supine positions 
during administration of TJ-43 or the placebo are shown in Figure 
1. LES pressure determined in the supine position was sig-
nificantly greater than when measured in the sitting position, as 
previously reported.
19,20,24 There was no statistically significant 
difference in LES pressure values determined during the admin-
istrations of TJ-43 and the placebo in the sitting position (14.4 ± 
0.7 vs 16.3 ± 1.3 mmHg; P = 0.798), whereas those in the su-
pine position were significantly different between them (28.0 ± 
3.5 vs 20.6 ± 1.8 mmHg; P = 0.047). Esophageal body peri-
staltic contractions measured at each segment 1, 2 and 3 
(proximal, middle and distal) of the esophagus in the sitting and 
supine positions are presented in Figure 2. In the 2 positions, the 
distal segment (segment 3) had the greatest peak contraction 
pressure. In addition, contraction pressure was greater in the su-
pine position for each segment. TJ-43 administration did not en-
hance the esophageal peristaltic contraction pressure in any in ei-
ther the sitting or supine position.
There was no statistically significant difference between the 
number of total post-prandial 3-hour reflux episodes during the 
TJ-43 and placebo administrations, though the number of reflux 
episodes tended to be higher during TJ-43 administration (43.1 
± 8.0/3 hours vs 34.2 ± 6.0/3 hours; P = 0.308). During the 
administration of TJ-43, the refluxate consisted of liquid only 
(71.7%), gas only (4.4%) and mixed (23.9%) reflux, while with 
the placebo the refluxate consisted of liquid only (79.8%), gas on-
ly (4.1%) and mixed (16.1%) reflux. Liquid only was the most 
frequently observed type of reflux in each post-prandial period, 
followed by mixed (Fig. 3). There were no significant differences 
for the ratios of weakly-acid and non-acid reflux between liquid 
only and mixed reflux events during administration with TJ-43 
and with the placebo. The percentage times at intraesophageal 
pH < 4.0 during the 3-hour post-prandial period are shown in 
Figure 4. There were no significant differences between the 
TJ-43 and placebo administrations regarding the percentage of 
esophageal acid (pH < 4.0) exposure time during the 3-hour 
post-prandial period (6.5 ± 2.0% vs 5.8 ± 1.3%; P > 0.999). 
On the other hand, the bolus clearance time of the gastro-
esophageal refluxate tended to be shorter during TJ-43 admin-
istration (25.9 ± 4.3 vs 37.0 ± 8.8 seconds; P = 0.139).Terumi Morita, et al
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Figure 2. Peak peristaltic contraction pressures in sitting and supine positions in segments 1 (A), 2 (B) and 3 (C). The distal segment (segment 3) had
a higher level of peristaltic pressure than the proximal segment (segment 1) in both the sitting and supine positions. There was no statistically significant
difference in regard to peristaltic pressure between the TJ-43 and placebo administration periods in the sitting and supine positions.
Figure 3. Mean post-prandial gastroesophageal reflux episodes, as 
determined by multi-channel impedance pH monitoring. The 3-hour 
post-prandial period was divided into three 1-hour periods. Liquid 
containing reflux (liquid only and mixed) was the major type observed 
during both the placebo and TJ-43 administrations.
Figure 4. Percentage of time at pH lower than 4 during the 3-hour 
post-prandial period. TJ-43 did not significantly change esophageal acid
exposure time.Rikkunshito and Esophageal Functions
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Discussion
Incompetence of the LES, decrease in esophageal motor 
function, reduced salivary secretion, and delayed gastric empty-
ing has been observed in GERD patients, while prokinetic agents 
are expected to improve those anti-reflux functions.
1 Indeed, ad-
ministration of cisapride was demonstrated to augment LES 
pressure, esophageal body contraction, salivary secretion and gas-
tric emptying, and also reported to effectively control reflux 
symptoms in patients with GERD.
25-29 Although cisapride has 
been used for treatment of GERD and shown to be equally effec-
tive as a histamine 2 receptor antagonist,
27 it was later withdrawn 
from the market because of the cardiac side effects.
30 At present, 
several other prokinetic agents are used for treatment of patients 
with various upper gastrointestinal symptoms, and their admin-
istration has been reported to be effective in patients with FD as 
well as with GERD. 
TJ-43 is an herbal medicine reported to be effective for sev-
eral upper gastro-intestinal symptoms, and widely administrated 
in Japan to patients with GERD and FD.
7,8,10,11,13 TJ-43 has also 
been reported to stimulate gastric motor activities and accelerate 
gastric emptying.
7,10-12 Improvement in esophageal acid clearance 
was also demonstrated following administration in pediatric pa-
tients with GERD.
9 However, the influence of TJ-43 on esoph-
ageal motor function and gastroesophageal reflux events in adults 
has not been fully investigated. 
In the present study, we conducted a detailed investigation of 
the effects of TJ-43 at a standard dose on esophageal motor activ-
ity and gastroesophageal acid/non-acid reflux. However, we did 
not find evidence of its efficacy for anti-reflux functions. On the 
other hand, TJ-43 elevated resting LES pressure in a supine po-
sition, and tended to accelerate esophageal bolus clearance and 
increase post-prandial reflux, though that latter finding is con-
trary to a previous report regarding the effect on esophageal mo-
tor function in pediatric GERD patients.
9 We employed a place-
bo-controlled double blind design in the present study, and also 
utilized highly sensitive and reliable methods to determine esoph-
ageal motor activity and gastroesophageal reflux. Therefore, the 
efficacy of TJ-43 for adult patients with GERD may not be re-
lated to augmentation of esophageal motor function, while in-
creased gastric motor function by administration of TJ-43 may 
relieve GERD symptoms. Investigation of the effects of TJ-43 
on esophageal sensory and perception mechanisms is important 
in a future study. 
Our study has some limitations. We administrated TJ-43 to 
healthy young volunteers and not GERD patients with reduced 
esophageal motor function and frequent gastro-esophageal reflux 
events, thus we did not evaluate the efficacy of TJ-43 on GERD 
symptoms. Additional investigations of patients with GERD are 
necessary to confirm the effects of TJ-43 on esophageal motor 
function.
In conclusion, this double-blind crossover study did not re-
veal a significant effect of TJ-43 on esophageal motor activity or 
gastroesophageal reflux events. Future studies are needed to clar-
ify its effects in patients with GERD. 
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